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ABSTRACT
Aims and background. A number of immunohistochemical markers have been sug-
gested as useful in the positive diagnosis of epithelioid mesothelioma. The most
widely used mesothelioma markers are thrombomodulin, calretinin, cytokeratin 5/6,
D2-40 and WT-1. Numerous investigations have demonstrated their variable sensitiv-
ity and specificity in differentiating epithelioid mesothelioma from lung adenocarci-
noma. However, data on the expression of these markers in other types of lung carci-
nomas are very limited. We evaluated the expression of these markers in a series of
172 primary carcinomas of the lung and in 75 epithelioid pleural mesotheliomas. 
Results. Thrombomodulin expression was found in squamous cell carcinomas (71%),
small cell lung carcinomas (11%), adenocarcinomas (4%), large cell carcinomas (50%),
large cell neuroendocrine carcinomas (25%) and in sarcomatoid carcinomas (10%).
Calretinin expression was common in small cell lung carcinomas (44%) and large cell
neuroendocrine carcinomas (25%), less common in squamous cell carcinomas (20%),
rare and focal in adenocarcinomas (4%) and sarcomatoid carcinomas (10%). Cytoker-
atin 5/6 was expressed in most of the squamous cell carcinomas (94.5%). Immunore-
activity was also found in large cell carcinomas (50%), sarcomatoid carcinomas (30%)
and rarely in adenocarcinomas (4%). D2-40 was consistently expressed in squamous
cell carcinomas (42%). Focal immunoreactivity was found in adenocarcinomas (3%).
WT-1 was focally present in one (2%) squamous cell carcinoma. 
Conclusions. These results indicate that some of the most commonly used mesothe-
lioma markers may react with different types of primary lung carcinomas. These da-
ta should be taken into consideration especially when dealing with small biopsy frag-
ments and poorly differentiated tumors.
Introduction
Several immunohistochemical markers have proven to be valuable in the positive
identification of mesothelioma1-4. Most investigations on this topic have concentrat-
ed principally on the differential diagnosis between epithelioid pleural mesothelioma
and lung adenocarcinoma. However, the pleura may be involved by other tumors, pri-
mary or metastatic, epithelial or epithelioid. Moreover, less differentiated and solid
epithelioid mesotheliomas may mimic a variety of tumors other than lung adenocar-
cinoma. An additional important issue regards the examination of small biopsy frag-
ments that may prove to be considerably challenging, as both morphology and im-
munohistochemical results may be ambiguous.
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Within positive mesothelial markers, thrombomodulin,
calretinin, cytokeratin 5/6 (CK 5/6), and more recently
Wilms’ tumor 1 (WT-1) protein and D2-40 monoclonal
antibody seem to have high sensitivity and/or specificity
in the positive diagnosis of epithelioid mesothelioma.
However, data on the expression of these markers in tu-
mors other than lung adenocarcinoma are very few.
The purpose of the present study was to evaluate the ex-
pression of the most commonly used mesothelial positive
markers in a series of primary epithelial lung tumors.
Materials and methods
Cases were retrieved from the files of the Division of
Pathological Anatomy of the Department of Medical and
Surgical Critical Care of the University of Florence. The
study group consisted of 172 cases of primary pulmonary
carcinomas, including 55 squamous cell carcinomas, 71
adenocarcinomas, 18 small cell carcinomas, 4 large cell
carcinomas, 4 large cell neuroendocrine carcinomas, 10
sarcomatoid carcinomas and 10 carcinoid tumors. Sev-
enty-five unequivocal epithelioid pleural mesotheliomas
from the same source were studied for comparison. Non-
small cell carcinomas and 12 small cell carcinomas de-
rived from surgically resected material; 6 small cell carci-
nomas derived from biopsy specimens. Each tumor was
reviewed and classified according to the World Health Or-
ganization’s criteria5. Pulmonary adenocarcinomas were
subtyped as follows: 56 were mixed subtype, 12 were aci-
nar, 2 were papillary and 1 was a solid subtype with
mucin production. Carcinoid tumors were all categorized
as typical. All mesothelioma cases were diagnosed by
currently accepted histologic criteria on hematoxylin and
eosin-stained sections combined with immunohisto-
chemistry5. Most of them showed a tubulo-papillary pat-
tern or a sheet-like, solid pattern.
Staining procedures were conducted on 4-µm-thick sec-
tions of paraffin-embedded tissue using an automated im-
munostainer (Ventana BenchMark XT, Tucson, AZ, USA).
The primary antibodies, their dilutions, and sources are
listed in Table 1. Appropriate positive and negative con-
trols were added on each automated immunohistochem-
istry run to confirm the sensitivity and specificity of each
antibody. The iVIEW DAB Detection Kit (Ventana) was
used as a revelation system. Immunoreactivity was scored
as negative (no immunostaining) or positive. The percent-
age of immunostained cells was recorded as follows: 1+
(1%-25%), 2+ (26%-50%), 3+ (51%-75%) 4+ (76%-100%).
Results
Primary carcinomas of the lung
The immunohistochemical results in the different
types of primary lung carcinomas are shown in Table 2.  
Table 1 - Antibodies used for immunohistochemical analysis
Molecule/antibody Clone Antibody dilution Source
Thrombomodulin 1009 1:30 Dako*
Calretinin Polyclonal Ready to use Ventana§
Cytokeratin 5/6 D5/16B4 Ready to use Ventana
D2-40 D2-40 Ready to use Ventana
WT-1 6F-H2 Ready to use Ventana
*Carpinteria, CA, USA. §Tucson, AZ , USA.
Table 2 - Immunohistochemical results in 172 primary lung tu-
mors
Markers Positive Grading of reactivity
reactions
n. % 0 1+ 2+ 3+ 4+
Squamous cell carcinoma 
(55 cases)
Thrombomodulin 39 71 16 8 10 8 13
Calretinin 11 20 44 8 2 1 0
CK 5/6 52 94.5 3 6 4 10 32
D2-40 23 42 32 4 4 6 9
WT-1 1 2 54 1 0 0 0
Small cell lung carcinoma 
(18 cases)
Thrombomodulin 2 11 16 2 0 0 0
Calretinin 8 44 10 3 2 0 3
CK 5/6 0 0 18 0 0 0 0
D2-40 0 0 18 0 0 0 0
WT-1 0 0 18 0 0 0 0
Adenocarcinoma (71 cases)
Thrombomodulin 3 4 68 3 0 0 0
Calretinin 3 4 68 3 0 0 0
CK 5/6 3 4 68 3 0 0 0
D2-40 2 3 69 2 0 0 0
WT-1 0 0 71 0 0 0 0
Large cell carcinoma (4 cases)
Thrombomodulin 2 50 2 1 0 0 1
Calretinin 0 0 4 0 0 0 0
CK 5/6 2 50 2 0 0 0 2
D2-40 0 0 4 0 0 0 0
WT-1 0 0 4 0 0 0 0
Large cell neuroendocrine 
carcinoma (4 cases)
Thrombomodulin 1 25 3 1 0 0 0
Calretinin 1 25 3 1 0 0 0
CK 5/6 0 0 4 0 0 0 0
D2-40 0 0 4 0 0 0 0
WT-1 0 0 4 0 0 0 0
Sarcomatoid carcinoma 
(10 cases)
Thrombomodulin 1 10 9 0 0 1 0
Calretinin 1 10 10 0 0 0 1
CK 5/6 3 30 7 0 0 1 2
D2-40 0 0 10 0 0 0 0
WT-1 0 0 10 0 0 0 0
Carcinoid tumor (10 cases)
Thrombomodulin 0 0 10 0 0 0 0
Calretinin 0 0 10 0 0 0 0
CK 5/6 0 0 10 0 0 0 0
D2-40 0 0 10 0 0 0 0
WT-1 0 0 10 0 0 0 0
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Thrombomodulin. Squamous cell carcinomas showed
the highest percentage of thrombomodulin-positive
cases and the highest score of reactivity. Thirty-nine
(71%) of 55 cases were found to be positive. The highest
percentage of positive cells (3+ and 4+) was found in
well- to moderately differentiated tumors. All keratiniz-
ing tumors showed strong and diffuse staining for the
marker (Figure 1A). Three (4%) of 71 adenocarcinoma
cases were thrombomodulin positive, and immunos-
taining was extremely focal (1+) with fewer than 5% pos-
itive cells. Small cell carcinomas showed thrombomod-
ulin immunoreactivity in 2 (11%) of 18 cases; both cases
showed less than 5% (1+) positive tumor cells. Throm-
bomodulin immunoreactivity was found in 2 (50%) of 4
large cell carcinomas; one case was focally positive, the
other case showed diffuse and strong (4+) immunos-
taining. Focal positivity was also found in 1 (25%) of 4
neuroendocrine large cell carcinomas. One (10%) of 10
sarcomatoid carcinomas showed moderately diffuse
(3+) thrombomodulin immunoreactivity. The tumor
was subtyped as pleomorphic carcinoma consisting of a
squamous cell carcinoma component associated with
more than 10% of malignant giant cells; both compo-
nents were thrombomodulin immunoreactive (Figure
1B). No carcinoid tumor was found to be positive. Re-
gardless of tumor histology, the staining pattern of
thrombomodulin was always typically membranous. 
Calretinin. Squamous cell carcinomas showed calre-
tinin positivity in 11 (20%) of 55 cases (Figure 1C). The
highest percentage of positive tumor cells was found in
3 well-differentiated keratinizing tumors (2+ in 2 cases
and 3+ in one case), and the moderately and poorly dif-
ferentiated calretinin-positive squamous cell carcino-
mas were all scored 1+. Three (4%) of 71 primary adeno-
carcinomas of the lung showed calretinin expression; all
cases showed less than 5% (1+) positive cells. The high-
est frequency of positivity for calretinin and the highest
percentage of calretinin-positive cells were found in
small cell carcinomas (Figure 1D). Globally, 8 (44%) of
18 cases were calretinin positive. Three cases showed
diffuse (4+) immunostaining. One of these cases was a
combined small cell carcinoma (small cell carcinoma
associated with an adenocarcinoma component) in
which calretinin was expressed only by the neuroen-
docrine cells. Two cases were scored 2+ and 3 cases
showed only focal (1+) immunoreactivity. Focal (<5%)
immunoreactivity was found in 1 (25%) of 4 large cell
neuroendocrine carcinomas. Strong and diffuse calre-
tinin immunostaining was found in one sarcomatoid
carcinoma. Carcinoid tumors were all found to be nega-
tive for this marker. All positive cases showed the typical
nuclear and cytoplasmic pattern of staining.
CK 5/6. All well-differentiated, keratinizing squamous
cell carcinomas were found to be diffusely and strongly
(4+) CK 5/6-positive. Moderately differentiated tumors
and non-keratinizing tumors were more commonly
scored 3+ and 2+. Cases with the lowest scores of im-
munoreactivity and the 3 (5%) negative cases were all
poorly differentiated tumors. Within adenocarcinomas,
3 (4%) of 71 were immunoreactive for CK 5/6. All posi-
tive cases (mixed adenocarcinomas, predominantly aci-
nar type) showed less than 5% of immunostained tumor
cells. Diffuse CK 5/6 immunostaining was found in 2
(50%) of 4 large cell carcinomas. Three (30%) sarcoma-
toid tumors were found to have diffuse or moderately
diffuse (4+ and 3+) CK 5/6 immunostaining. Two posi-
tive tumors were classified as pleomorphic carcinomas
composed of squamous cell carcinoma associated with
a giant cell component and squamous cell carcinoma
associated with a spindle cell component. The third
positive case was subtyped as spindle cell carcinoma.
Positive immunoreactions were found within the squa-
mous cell component, the giant cell and the spindle cell
component. No CK 5/6 immunostaining was found in
small cell carcinomas or in carcinoid tumors.
D2-40. Immunostaining with the monoclonal anti-
body D2-40 was found to be positive in 23 (42%) of 55
squamous cell carcinomas (Figure 1E). Immunoreactiv-
ity was graded 4+ in 9 cases, 3+ in 6 cases, 2+ in 4 cases
and 1+ in 4 cases. Most positive cases were well- and
moderately differentiated tumors. Only 2 poorly differ-
entiated squamous cell carcinomas were D2-40-posi-
tive, both showing diffuse and strong immunoreactivity
in 80% and 100% of tumor cells, respectively. The im-
munostaining was more evident in the outer cells of the
neoplastic nests with a membranous pattern of staining
along the entire surface of the cells. Two (3%) of 71 ade-
nocarcinoma cases were focally (1+) D2-40-positive;
both positive adenocarcinomas were mixed subtype
with a predominantly acinar pattern of growth. No pos-
itivity at all was found in any of the other cases includ-
ed in the study. Only membranous staining was consid-
ered as a positive immunoreaction.  
Wilms’ tumor 1 protein. WT-1 protein was negative in
all our study cases, except for 1 case of moderately dif-
ferentiated squamous cell carcinoma in which few tu-
mor nests showed nuclear WT-1 positivity (Figure 1F).
Pleural epithelioid mesothelioma
The immunohistochemical results of the mesothe-
lioma markers in epithelioid mesotheliomas are shown
in Table 3. Each mesothelioma marker was found to be
positive in a high percentage of epithelioid mesothe-
liomas. Thrombomodulin was found to be positive in 58
(77%) mesothelioma cases. Grading of reactivity
showed heterogeneous results, as shown in Table 3. The
lowest percentage of positive cells was observed in the
less differentiated tumors with a solid pattern of growth.
Immunoreactivity was often limited to the superficial
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Figure 1 - Immunoreactivity of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in different types of primary carcinomas of the
lung. Strong membrane immunostaining for thrombomodulin in a squamous cell carcinoma of the lung (A). Diffuse and strong thrombo-
modulin immunostaining in the giant cell component of a pleomorphic carcinoma of the lung (B). Nuclear and cytoplasmic calretinin im-
munostaining in a moderately differentiated squamous cell carcinoma of the lung (C). Small cell carcinoma of the lung with diffuse nuclear
and cytoplasmic immunostaining for calretinin (D). D2-40-positive well-differentiated squamous cell carcinoma; the pattern of staining is
membranous along the entire surface of the cells and it is clearly more evident in the outer cells of the neoplastic nests (E). Focal nuclear WT-
1 immunostaining in a poorly differentiated squamous cell carcinoma (F).
A
C
E
B
D
F
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cells, being negative in the deeper portions of the tu-
mor. The staining pattern was always typically membra-
nous.
Calretinin expression was shown by all mesothelioma
cases. The staining was nuclear and cytoplasmic, strong
and diffuse (3+ or 4+) in all cases.
Cytoplasmic cytokerkatin 5/6 immunostaining was
shown in 70 (93%) mesotheliomas. Fifty-nine cases were
moderately or diffusely immunoreactive (3+ and 4+),
whereas in 16 cases the grading of reactivity was focal
(1+) or mild (2+).
Seventy-three (97%) mesotheliomas stained with the
monoclonal antibody D2-40. Immunoreactivity was
strong and diffuse (4+) in 50 cases and moderately dif-
fuse (3+) in 19 cases; 4 cases showed focal staining (1+).
In most cases, the staining occurred along the apical
surface of the cells in a continuous pattern. In solid ar-
eas, the staining was milder and sometime discontinu-
ous.
WT-1 immunoreactivity was seen in 67 (89%)
mesotheliomas. Most cases showed strong, diffuse or
moderately diffuse nuclear staining. Negative cases
showed a solid pattern or a poorly differentiated, pleo-
morphic histology.
Discussion
A large number of immunohistochemical markers for
the positive diagnosis of epithelioid mesothelioma has
proven to be valuable1-4,6. Specificity and sensitivity of
mesothelioma markers have been mainly and exten-
sively studied with regard to the differential diagnosis
between epithelioid mesothelioma and lung adenocar-
cinoma1-4,6. Yet, mesothelioma is notorious for pheno-
typic versatility, both from case to case and even within
the same tumor. The various histologic patterns and cy-
tomorphologic features of the tumor underlie its capac-
ity to mimic many other neoplasms involving the pleu-
ra or adjacent tissues. Moreover, besides pulmonary
adenocarcinoma, lung carcinomas in general are inher-
ently heterogeneous tumors that show a wide range of
cytohistological aspects within each major histotype.
Additionally, morphology and immunohistochemical
results may both be confusing when dealing with biop-
sy specimens, due to limited tissue samples, artefacts
and non-specific changes.
Thrombomodulin is a 75-kDa transmembrane glyco-
protein that exerts anticoagulant activity7. It is ex-
pressed in a variety of tumors other than those of vas-
cular origin, such as mesothelioma, trophoblastic tu-
mors, squamous and transitional cell carcinomas8,9.
Since the first studies on the value of this marker in dif-
ferentiating epithelioid mesothelioma from lung ade-
nocarcinoma, results on its sensitivity and specificity
have been controversial8. The reported percentage val-
ues of positive mesotheliomas are highly variable, as
highly variable as the percentage of thrombomodulin
expression in lung adenocarcinomas4,8. Such discrepan-
cies have been widely analyzed and attributed to a vari-
ety of possible factors8. Nonetheless, thrombomodulin
was the first positive mesothelioma marker that could
be used on formalin-fixed, paraffin-embedded tissue10.
In our experience11,12, including the present study,
about two-thirds of mesotheliomas expressed thrombo-
modulin, but the grading of reactivity was heteroge-
nous, with many cases showing only focal staining. As
regards the expression of thrombomodulin in lung car-
cinomas other than adenocarcinomas, data from the lit-
erature are reported in Table 4. Most investigations con-
sidering large series of squamous cell carcinomas re-
ported diffuse expression of the marker8,13,14. In our in-
vestigation, a large number (71%) of squamous cell car-
cinomas was found to be thrombomodulin positive. As
previously reported, strong and diffuse immunostain-
ing characterized the most well-differentiated keratiniz-
ing squamous cell carcinomas13. Within the remaining
histotypes, other than adenocarcinoma and squamous
cell carcinoma, data from the literature are very few
(Table 4). Concerning neuroendocrine tumors, results
are extremely variable due to differences in the number
of cases examined in the different studies8,14,15. The
largest number of cases was analyzed by Miettinen et
al.14 The authors found thrombomodulin-positive im-
munostaining in 27% of small cell carcinomas and in
18% of large cell neuroendocrine carcinomas. In our
study, thrombomodulin immunoreactivity was focally
observed in 2 (11%) of 18 cases of small cell carcinoma
and in 1 of 4 cases of large cell neuroendocrine carcino-
mas. Carcinoid tumors were all found to be thrombo-
modulin negative in the investigation by Ordóñez8. The
same results were obtained in the present study. Within
undifferentiated large cell carcinomas, no immunoreac-
tivity was found in the study by Ordóñez8, whereas Mi-
ettinen et al.14 found 29 (25%) thrombomodulin-posi-
tive large cell carcinomas out of 117 cases. In our limit-
ed series of cases, we found 2 (50%) thrombomodulin-
positive large cell carcinomas, one focally positive and
the other one diffusely positive. Discordant results on
thrombomodulin expression in sarcomatoid carcino-
mas of the lung have been reported8,14-18. In fact, posi-
Table 3 - Immunohistochemical results in 75 epithelioid
mesotheliomas
Marker Positive Grading of reactivity
reactions
No. % 0 1+ 2+ 3+ 4+
Thrombomodulin 58 77 17 21 21 11 5
Calretinin 75 100 0 0 0 20 55
CK 5/6 70 93 5 7 9 11 43
D2-40 73 97 2 4 0 19 50
WT-1 67 89 8 1 7 30 29
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tive values in the different studies ranged from 0% to
43.5%, but again, the number of cases studied was ex-
tremely variable. In the present study, thrombomodulin
positivity was found in 1 (10%) sarcomatoid carcinoma
(giant cell carcinoma) with moderately diffuse im-
munostaining.
In summary, the use of this marker in differentiating
mesothelioma from lung adenocarcinoma has certainly
declined since the identification of more sensitive posi-
tive mesothelioma markers. Moreover, such common
thrombomodulin positivity in squamous cell carcinoma
and, less frequently, in other histotypes further limits
the value of this marker in the positive diagnosis of
mesothelioma.
Calretinin is a 29-kDA protein that is a member of the
EF-hand family of calcium-binding proteins. First de-
scribed in the central and peripheral neural tissues, cal-
retinin expression has also been reported in a variety of
epithelial and non-epithelial human tissues under nor-
mal and neoplastic conditions19,20. Since the first study19
on the use of the marker in the differential diagnosis be-
tween mesothelioma and lung adenocarcinoma, calre-
tinin has almost always been considered the most useful
marker for the positive diagnosis of mesothelioma4,21. In
the present study, calretinin was diffusely and strongly
positive in all mesothelioma cases, thus confirming the
results of previous investigations. Moreover, only 3 (4%)
of 71 lung adenocarcinomas showed focal calretinin im-
munostaining, in accordance with the well-known high
specificity of this marker in the differential diagnosis be-
tween the latter tumor and epithelioid mesothelioma.
Relatively few studies have been published on calretinin
immunoreactivity in squamous cell carcinoma of the
lung14,15,19-23. The data from previous studies are shown
in Table 4. Grading of reactivity has almost always been
reported as focal or moderate. A correlation between
grade of differentiation and calretinin expression was re-
ported in the investigation by Miettinen et al.14; the au-
thors found a higher grading of reactivity in nonkera-
tinizing tumors. In the current study, 11 (20%) of 55
squamous cell carcinomas were calretinin positive.
Grading of reactivity was focal in most cases. In contrast
with previous results, we found higher reactivity score
values in well-differentiated keratinizing tumors. Calre-
tinin expression in neuroendocrine carcinomas has
been evaluated in few reports14,15,19,20. Concerning small
cell lung carcinoma, most studies found high percent-
ages of calretinin-positive cases with values ranging
from 41% to 49%14,20. Large cell neuroendocrine carcino-
mas have been evaluated only in one previous study14,
showing 45% calretinin-positive cases. We found calre-
tinin positivity in 50% of small cell carcinomas and in
25% of large cell neuroendocrine carcinomas. In con-
trast to high-grade neuroendocrine carcinomas, no cal-
retinin immunoreactivity was found in our series of car-
cinoid tumors or in the previous study by Doglioni et
al.19 With regard to large cell carcinoma, the largest se-
ries was evaluated by Miettinen et al.14, who reported
38% calretinin-positive cases. In the current study, no
calretinin immunoreactivity was observed. Finally, re-
ported results on the expression of calretinin in sarco-
matoid carcinomas have been controversial14,16-18,24-26.
Positive calretinin immunostaining has been reported in
both the spindle cell and the giant cell component of sar-
comatoid carcinomas. The data from the literature
(Table 4) indicate about 60% positivity, although some
results are questionable since cytoplasmic staining
alone was considered to be positive26. Our investigation
showed one giant cell carcinoma with diffuse and strong
calretinin staining.
In summary, calretinin seems to be more frequently
expressed in lung carcinomas other than adenocarcino-
ma. In particular, neuroendocrine carcinomas and sar-
comatoid carcinomas may exhibit high percentages of
positive tumor cells, whereas squamous cell carcinomas
are more often focally immunoreactive.
Table 4 - Positive mesothelioma markers reported in lung carcinomas other than adenocarcinoma
Marker Histotype
SCC SCLC LCC LCNEC CT SC
Any Any Any Any Any Any 
positivity positivity positivity positivity positivity positivity 
of total of total of total of total of total of total
cases (%) Ref. cases (%) Ref. cases (%) Ref. cases (%) Ref. cases (%) Ref. cases (%) Ref.
Trombomodulin 94/188 (50) 8,13-15 11/51 (22) 8,14,15 29/117 (25) 8,14 6/33 (18) 14 0/16 (0) 8 19/45 (42) 8,14-18
Calretinin 71/242 (29) 14,15,19-23 27/60 (45) 14,15,20 50/157 (32) 14,20,21 15/33 (45) 14 0/2 (0) 19 36/60 (60) 14,16-18,
24,25
Cytokeratin 5/6 116/124 (94) 14 11/41 (27) 14,15,27, 70/125 (56) 14,31 6/42 (14) 14,27 ND 5/40 (12) 14-17
31
D2-40 73/148 (49) 23,34,39,40 0/53 (0) 39,40 ND 1/11 (9) 40 ND 26/51 (51) 18,25,41
WT-1 0/58 (0) 23,44-46 1/24 (4) 45,47 0/1 (0) 45 ND 0/1 (0) 45 7/35 (20) 18,44,45
SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; CT, car-
cinoid tumour; SC, sarcomatoid carcinoma; ND, no data.
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CK 5/6 are high-molecular-weight basic cytokeratins.
They are normally expressed in basal cells of complex
epithelia such as respiratory and squamous epithelia as
well as in the basal-myoepithelial cell layer of the
prostate, breast and salivary glands27. This keratin is
typically present in normal mesothelial cells and in
mesotheliomas27,28. Significant differences in the cytok-
eratin expression pattern between lung adenocarcino-
ma and mesothelioma have been highlighted28,29. Since
the introduction of the commercially available mono-
clonal antibody D5/16B4 anti-CK 5/6, most investiga-
tions have indicated high sensitivity and specificity of
this marker30,31. Less specificity of CK 5/6 has been doc-
umented when analyzing adenocarcinomas of various
tissue origins other than the lung31. In accordance with
previous investigations, we found a high percentage
(97%) of CK 5/6-positive mesotheliomas. In our experi-
ence, diffuse immunostaining is observed mostly in
well-differentiated tubular or papillary epithelioid
mesotheliomas, whereas less differentiated tumors of-
ten show only mild and focal CK 5/6 immunostaining.
Few positive CK 5/6 tumor cells were found in 3 adeno-
carcinoma cases. CK 5/6 is typically expressed in most
squamous cell carcinomas. Only few studies have inves-
tigated the expression of CK 5/6 in lung carcinomas oth-
er than adenocarcinoma and squamous cell carcinoma.
CK 5/6 is almost always found to be negative in high-
grade neuroendocrine tumors14,15,27,31. In our series, all
high-grade neuroendocrine tumors and all carcinoid
tumors were CK 5/6 negative. The data reported on CK
5/6 immunoreactivity in undifferentiated large cell car-
cinomas are few and controversial14,31. In our study, 2
(50%) cases showed strong and diffuse CK 5/6 im-
munostaining, but the number of cases is too small to
make any considerations. Positivity for CK 5/6 in sarco-
matoid carcinomas has been reported in the squamous
cell component of pleomorphic carcinomas, in spindle
cell carcinomas and in giant cell carcinomas14-17. In the
present study, we observed 3 (30%) CK 5/6-positive sar-
comatoid carcinomas (1 spindle cell carcinoma and 2
pleomorphic carcinomas).
In summary, CK 5/6 is typically expressed in mesothe-
lioma and lung squamous cell carcinoma. These cytok-
eratins may also be expressed in large cell carcinomas
and in sarcomatoid carcinomas of the lung.
D2-40 is a monoclonal antibody directed against hu-
man podoplanin, a 38-kD transmembrane mucin-type
glycoprotein32. Until recently, the clinical use of D2-40
included the demonstration of lymphatic invasion by
primary tumors and its use as a marker of tumors with
lymphatic differentiation33. Subsequently, data from the
literature have demonstrated the expression of D2-40 a
variety of different neoplasms, including mesothe-
lioma33-35. Most studies have indicated the utility of D2-
40 differentiating epithelioid mesothelioma from lung
adenocarcinoma4,34-39. Our results are in accordance
with those of the literature: 93% of the mesothelioma
cases were D2-40-positive, whereas adenocarcinomas
showed immunoreactivity in 3% of the cases. Data from
the literature on D2-40 immunoreactivity in squamous
cell carcinomas show positive immunostaining in about
50% of the evaluated cases23,34,39,40. In the present study,
D2-40 was found to be positive in 23 (42%) of 55 squa-
mous cell carcinomas. Different results from previous
investigations were observed concerning the grading of
reactivity, since we found 65% of squamous cell carci-
nomas with high percentages of D2-40-positive cells. In
agreement with Ordóñez23, immunostaining was
stronger in the peripheral cells of the tumor nests and
the staining pattern was typically membranous. More-
over, differences in D2-40 expression were found in re-
lation to the grade of differentiation. In fact, all but 2
D2-40-positive cases were classified as well- or moder-
ately differentiated tumors. We found no comments on
this issue in previous investigations. With regard to neu-
roendocrine tumors, data from the literature are very
few39,40 and demonstrate no immunoreactivity in small
cell lung carcinomas or, except for one case, in large cell
neuroendocrine carcinomas40. So far, there are no pub-
lished data on the expression of D2-40 in carcinoid tu-
mors. Small cell carcinomas, large cell neuroendocrine
carcinomas and carcinoid tumors included in the pres-
ent study were all found to be D2-40-negative. The ex-
pression of D2-40 in sarcomatoid carcinomas of the
lung has been reported in recent studies18,25,41. Im-
munostaining has been described mainly as focal
and/or weak. In the present study, no D2-40-positive
immunostaining was observed in sarcomatoid carcino-
mas. 
In summary, D2-40 is a highly sensitive and specific
mesothelial marker when differentiating epithelioid
mesothelioma from lung adenocarcinoma, large cell
carcinomas and neuroendocrine tumors. D2-40 positiv-
ity has been reported in about 40% to 50% of squamous
cell carcinomas. In our opinion, such a common D2-40
positivity limits the value of this marker in differentiat-
ing squamous cell carcinoma from epithelioid
mesothelioma, especially when dealing with small
biopsy fragments.    
The WT-1 tumor suppressor gene, located on the
short arm of chromosome 11 (11p13), encodes a protein
with the structural features of a DNA-binding transcrip-
tion factor42,43. Currently, its main practical use as a di-
agnostic marker concerns Wilms’ tumor, epithelioid
mesothelioma, ovarian serous cancers, serous carcino-
ma of the peritoneum and rhabdomyosarcomas. As for
other positive mesothelioma markers, the value of WT-1
has been investigated mainly in differentiating epithe-
lioid mesothelioma from lung adenocarcinomas4,44. De-
pending on the type of antibody used, rabbit polyclonal
antibody against WT-1 or monoclonal antibody clone
6F-H2, nuclear positivity for the marker in epithelioid
mesothelioma has been reported to range from 43% to
96%44. In accordance with most studies that used the
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monoclonal antibody 6F-H2, we found WT-1 im-
munoreactivity in a high percentage (89%) of epithe-
lioid mesotheliomas; negative cases were those with
less differentiated histology. As reported by most inves-
tigations, despite less sensitivity of WT-1 in comparison
with calretinin and D2-40, we found very high specifici-
ty (100%) of this marker in differentiating epithelioid
mesothelioma from lung adenocarcinoma. Very little in-
formation is available on WT-1 immunoreactivity in
lung tumors other than adenocarcinoma (Table 4)23,44-
47. All the data from the literature show very high speci-
ficity of this marker. More recently, the investigation by
Takeshima et al.18 reported WT-1 immunoreaction in 7
(36.8%) of 19 lung sarcomatoid carcinomas. However,
most cases in the study showed cytoplasmic staining,
which, in our opinion, should be considered as negative
immunostaining. To the best of our knowledge, our
study reports the largest series published to date on the
expression of WT-1 in primary lung carcinomas. We
found focal, nuclear WT-1 immunoreactivity only in one
case, a squamous cell carcinoma.
In summary, in our experience and consistent with
most investigators, WT-1 seems to be slightly less sensi-
tive than other available positive mesothelioma mark-
ers, but very specific in differentiating epithelioid
mesothelioma from primary carcinomas of the lung.
In conclusion, in accordance with previous published
data, the present study showed thrombomodulin, calre-
tinin, CK 5/6, D2-40 and WT-1 to be useful in the identi-
fication of most mesothelioma cases. These markers
may react with different types of primary pulmonary
carcinomas with a variable frequency. Thrombomod-
ulin, CK 5/6 and D2-40 may be expressed especially in
squamous cell carcinomas, whereas calretinin may be
positive in high-grade neuroendocrine carcinomas. WT-
1 seems to be the most specific positive mesothelioma
marker when differentiating epithelioid mesothelioma
from primary lung carcinomas. The pattern of im-
munostaining is important for certain markers such as
calretinin and WT-1: the former requires both nuclear
and cytoplasmic staining, the latter should show only
nuclear staining. These data should be taken into con-
sideration when dealing with biopsy specimens and
poorly differentiated tumors. Thus, especially in cases
of small pathological samples, accurate morphological
examination and appropriate clinical, radiological and
surgical findings are mandatory to select the most sen-
sitive and specific positive and negative mesothelial
markers.
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